Benzoic acid derivatives such as carinamide (4-carboxy-phenyl-methane-sulfonanilide) have been reported to be effective uricosuric agents, presumably by blocking renal tubular resorptions of uric acid. Benemid (p-[di-n-propylsulfamyl] -benzoic acid), another compound of this type, has recently become available. In patients with tuberculosis undergoing treatment with PAS (p-aminosalicylic acid) the simultaneous administration of Benemid tended to prevent the rapid renal excretion of the PAS. Since this effect was presumably due to some blocking of renal tubular activity, it became of interest to test the effect of Benemid on uric acid excretion.
The present study was carried out on two subjects. One was an idiopathic hyperuricemic subject (J. H. T.) who appeared from previous studies to have a normal uric acid metabolism; the other subject (W. S.) was known to be suffering from gouty arthritis and had been studied previously in this laboratory.
Before and after a course of Benemid therapy, N15 labeled uric acid was injected intravenously for the determination of uric acid pool size and turnover rate. Uric acid excretion was followed quantitatively by the isotope dilution method.
EXPERIMENTAL PROCEDURES
Each subject was injected intravenously with N1" labeled uric acid (25-50 mg, 16 atom per cent excess) and urine samples were collected for several days. The subject then began the daily ingestion of 2 gm of Benemid. On the third day of this regimen, labeled uric acid was 1 Part of the data from this paper may be submitted by Royden Rand to the Graduate School of the University of Buffalo in partial fulfillment of requirements for the degree From standard solutions of uric acid it was demonstrated that this method under conditions comparable to those used for urine, gave results accurate to within 2 per cent. This implied that for a daily excretion of 800 mg the determination would be accurate to within 16 mg. It was believed that such results were considerably better than could be expected from any of the usual methods for the quantitative determination of urinary uric acid. Furthermore, the material determined as uric acid was uric acid, not a mixture of uric acid and nonuric acid chromogen as in the usual colorimetric procedures.
Serum uric acid concentrations were determined by the method of Folin (2) . Since these values were only used as a clinical guide and not as the basis of further calculation, it is not so necessary that they be highly specific for uric acid. Figure 1 is a graph of the isotope concentration of the urinary uric acid of the non-gouty subject (J. H. T.) in the period before the ingestion of Benemid. On day 160, Benemid ingestion was begun and was continued through day 166 . Figure  2 shows the isotope concentration after the injection of labeled uric acid on day 163 and during the period of Benemid ingestion. The uric acid pool size in the control period was calculated by assum-889 Benemid is an effective tubular blocking agent and inhibits the resorption of uric acid. Under such circumstances some uric acid from the body pool should be excreted, leading to a decrease in the pool size and an increase in the turnover rate. (If the rate of synthesis of body uric is constant then a decrease in the pool size is equivalent to an increase in the turnover rate in pools per day.)
RESULTS
In Figure 3 , the daily uric acid output of the same subject has been represented by a bar graph. On the same graph has been plotted the serum uric acid concentration. The fall in serum uric acid concentration and the rise in urinary uric acid excretion during Benemid therapy is apparent.
The mean daily uric acid excretion during an 11 day control period which included all days of urinary collection before and after Benemid administration was 830 mg. The "extra" uric acid excreted during the seven days on Benemid was 2705 mg. This was several times the magnitude of the 498 mg decrease in the immediate pool size after Benemid administration. At least two explanations might be offered for this. One is that this "extra" uric acid is not derived exclusively from the immediate pool but from a more remote pool of uric acid. At present there does not seem to be any good way of testing this hypothesis. Another explanation is that with the renal tubules blocked, more exogenous uric acid finds its way into the urine. This hypothesis cannot be rigorously proved, but there are isolated facts that tend to support it. One is that subjects on Benemid continue to excrete "extra" uric acid as long as they continue taking the drug. Since the decrease not been accounted for as urinary uric acid, it was assumed that this amount had been disposed of by another route, probably catabolism since there has been scattered evidence for such a process (4, 5) . Before and during the second N15 uric acid injection period the subject had been taking Benemid. The injected uric acid was excreted quickly, and 89.6-per cent was recovered as urinary uric acid. This is consistent with the hypothesis that one or more alternate mechanisms is competing for the uric acid that would otherwise be excreted by the kidney. If the N15 concentration of the body uric acid pool is quickly reduced, the amount of the injected uric acid that can escape by the alternate routes will be reduced. Benemid does cause such a rapid decrease in the N15 uric acid concentration of the body pool, presumably by blocking resorption of urinary uric acid. .1. The second subject of this study, W. S., although suffering from gouty arthritis, responded to Benemid therapy in much the same way as the first subject. Benemid ingestion was begun on day 181 and continued through day 186. As can be seen from Figure 6 , the uric acid pool size in his control period was 2205 mg and the turnover rate was .484 pools per day. After Benemid therapy (Figure 7 ) his pool size fell to 1622 mg and the turnover rate rose to 1.006 pools per day. This paralleled a marked drop in serum uric acid concentration as shown in Figure 8 . Yet the drop in the size of the immediate pool was only 573 mg while the "extra" uric acid excreted during the six days on Benemid was 4889 mg as can be seen from the same figure. It is quite possible, especially in the gouty subject, that some of this "extra" uric acid is derived from a pool much larger than the immediate pool. There is also the suspicion that at least part of the "extra" uric acid is derived from dietary sources.
One striking difference between the behavior of the non-gouty and gouty subjects was the amount of the injected dose of isotopic uric acid recovered as urinary uric acid. In the gouty subject this was 98.9 per cent as can be seen from Table I In the normal and the gouty subjects the amount of body uric acid that would immediately equilibrate with injected N15 uric acid decreased markedly after Benemid therapy, and the turnover rate of the body uric acid pool increased greatly.
The amount of "extra" uric acid that was excreted during the period of Benemid therapy was much greater than the amount that disappeared from the immediate pool. Some of this "extra" uric acid, especially in the gouty subject, might have come from a more remote depot of uric acid but other evidence suggests that the diet, under the conditions of this experiment, may have contributed to this "extra" uric acid.
In the control period of the non-gouty subject only 71.5 per cent of the injected N15 uric acid was recovered as urinary uric acid up to the time when its excretion ceased. During Benemid therapy the recovery of a second dose of N15 uric acid was 89.6 per cent. This was explained as being due to the more rapid excretion of the N15 uric acid in the second period, thus decreasing the time during which the labeled uric acid could be disposed of by a competing catabolic or other disposal route. The recovery of injected N15 uric acid in the total of both periods of the gouty subject was 98.9 per cent up to the time when excretion of the isotope had virtually ceased. This gouty subject apparently did not catabolize uric acid or dispose of it in any other way than by urinary excretion.
Since in the gouty subject all of the injected labeled uric acid was excreted as urinary uric acid, it was possible to calculate the uric acid pool size at succeeding time periods. The size of the pool in the control period of this subject rose from approximately 2,700 mg at the time of injection of the labeled uric acid to 4,700 mg within three days. It could not be reliably estimated thereafter. After Benemid therapy the pool size fluctuated around 1,600 mg.
Benemid was shown, both in the gouty and nongouty subject, to be a potent uricosuric agent, this action being associated with a reduction in the serum urate concentration and a reduction in the pool size of body uric acid.
